Exelixis

Exelixis Receivables

The Accounts Receivable of Exelixis (EXEL) as of Nov 8, 2026 is 286.92 M USD. In the previous year, Accounts Receivable was 214.80 M USD — a change of 33.57% (higher).

Receivables

286.92 MUSD

YoY

33.57%

Last updated:

Accounts Receivable of Exelixis is 2025 286.92 M USD. Accounts Receivable of Exelixis was 2024 214.80 M USD. It decreases by 33.57% higher compared to the previous year.

The Exelixis Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2014
4.90 M USD
Jan 1, 2015
5.20 M USD
Jan 1, 2016
40.40 M USD
Jan 1, 2019
120.20 M USD
Jan 1, 2020
160.90 M USD
Jan 1, 2021
282.70 M USD
Jan 1, 2022
214.80 M USD
Jan 1, 2025
286.92 M USD
The Exelixis Receivables history
YEARReceivablesYoY
286.92 MUSD+33.57%
214.80 MUSD-24.02%
282.70 MUSD+75.70%
160.90 MUSD+33.86%
120.20 MUSD+197.52%
40.40 MUSD+676.92%
5.20 MUSD+6.12%
4.90 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

Accounts Receivable of Exelixis is 286.92 M USD in 2025.

Accounts Receivable of Exelixis changed from 214.80 M USD to 286.92 M USD, representing a 33.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Exelixis since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Exelixis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Exelixis

All Key Metrics — Exelixis